Web25 nov 2024 · DS8201-A-U206 2024-004781-94 ( EudraCT Number ) First Posted: November 25, 2024 Key Record Dates: Last Update Posted: October 12, 2024 Last Verified: October 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes: Plan Description: De-identified ... Web15 mag 2024 · Protocol DS8201-A-U201 Version 1.0, 15May2024 Proprietary and Confidential Page 7 Total bilirubin ≤ 3 × ULN; aspartate aminotransferase (AST)/alanine …

Daiichi Sankyo DS8201-A-U201 (DS-8201a) - Health Research …

Web1 apr 2024 · DS8201-A-U201: Breast cancer: Yes: HER2-targeted therapy in combination with chemotherapy: Yes: 20%: Not provided: 42: Vismodegib: SHH4476g: Skin cancer: No: Radiation therapy or chemotherapy: Yes: mBCC 10%: No therapeutic options exist for these patients and spontaneous responses have not been reported in this disease d: 43: Yes: Web5 Trastuzumab deruxtecan (DS-8201) • Imfinzi • Capivasertib • Oral SERD 2010s 2000s 1990s 1980s 1970s 2024s Building on our rich heritage in Breast Cancer Adds a late stage high value asset to our innovative pipeline favicon markup

College of Medicine

Web5 Trastuzumab deruxtecan (DS-8201) • Imfinzi • Capivasertib • Oral SERD 2010s 2000s 1990s 1980s 1970s 2024s Building on our rich heritage in Breast Cancer Adds a late … Web23 apr 2024 · DS8201-A-U204 2024-004781-94 ( EudraCT Number ) JapicCTI-183916 ( Registry Identifier: JAPIC ) First Posted: April 23, 2024 Key Record Dates: Results First Posted: May 17, 2024: Last Update Posted: January 20, 2024 Last Verified: January 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes WebApproved 14-Dec-2024 DS8201-A-U201 Clinical Results Summary 6 How many participants had tumors that completely disappeared or became at least 30% smaller … favicon machen